Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Mahidol University
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06498323CT.gov Intravenous TNK vs TPA for AIS Treatment on MSU,a Prospective Multicenter RCT | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Thrombotic Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tenecteplase (this asset) | Mahidol University | Approved | BB · 65 |
| Rivaroxaban | Shanghai Zhongshan Hospital | P4 | BBB |
| Aspirin | China National Center for Cardiovascular Diseases | P4 | BBB |
| Apixaban | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | P4 | BB |
| Dabigatran | St. Antonius Hospital | P4 | BB |
| Warfarin | China National Center for Cardiovascular Diseases | P4 | BB |
| Enoxaparin | Helsinki University Central Hospital | P4 | BB |
| Tinzaparin | Helsinki University Central Hospital | P4 | BB |
| Clopidogrel | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | P4 | BB |
+15 more in the Thrombotic Disease cohort
Other indications for Tenecteplase
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Basilar Artery Occlusion | — | P4 | BBB · 75 |
| Stroke Disorder | — | P4 | BBB · 73 |
| Ischemic Stroke | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tenecteplase in Thrombotic Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tenecteplase-thrombotic-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →